John J.V. McMurray
University Medical Center Groningen
8 papers in the Anchorcite directory, published between 2010 and 2020, cited 61,411 times in total.
ORCID profileResearch topics
- Atrial Fibrillation Management and Outcomes · 4 papers
- Heart Failure Treatment and Management · 3 papers
- Acute Ischemic Stroke Management · 3 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Cardiac pacing and defibrillation studies · 2 papers
- Diabetes Treatment and Management · 2 papers
Frequent co-authors
- Dan Atar · 4 papers
- Piotr P. Ponikowski · 4 papers
- Hein Heidbüchel · 3 papers
- Bogdan Alexandru Popescu · 3 papers
- Ulrich Schotten · 3 papers
- Bülent Görenek · 3 papers
- Isabelle C. Van Gelder · 3 papers
- José Luis Zamorano · 3 papers
Papers
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology · 2013 · 12,687 citations
Introduction 1.1. Methodology and Evidence ReviewThe recommendations listed in this document are, whenever possible, evidence based.An extensive evidence review was conducted through October 2011 and includes selected other references through April 2013.Searches were extended to studies, reviews, and other evidence…
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine · 2011 · 9,052 citations
BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a…
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine · 2014 · 7,166 citations
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients…
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal · 2016 · 6,593 citations
The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO) ... ...…
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace · 2016 · 6,438 citations
2 Representing the European Stroke Association (ESO) ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies Reviewers can be found in the Appendix.ESC entities having participated in the development of this document: Associations: European Association for Cardiovascular Prevention and…
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine · 2020 · 5,992 citations
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. METHODS: of body-surface area and…
- Guidelines for the management of atrial fibrillationEuropean Heart Journal · 2010 · 5,954 citations
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Over 6 million Europeans suffer from this arrhythmia, and its prevalence is estimated to at least double in the next 50 years as…
Metadata from OpenAlex (CC0).